{"Clinical Trial ID": "NCT00228943", "Intervention": ["INTERVENTION 1:", "- Tryptophan at full strength, acute depletion", "[Unspecified]", "INTERVENTION 2:", "Half-Strength Tryptophan Depletion - Control", "[Unspecified]"], "Eligibility": ["Incorporation criteria:", "At least 18 years of age", "Willingness and ability to give informed consent", "\u25cf Report daily hot flashes", "\u2022 Ability to read, write and speak English", "One menopause to limit sample variability (> 12 months of amenorrhea)", "More than a month, but less than 5 years after treatment (surgery, radiation therapy, chemotherapy) for non-metastatic breast cancer.", "These criteria allow for the inclusion of women successfully treated for recurrent breast cancer, as there is no known reason to exclude them. Menopausal status is assessed using self-reports due to problems in the reliable measurement of follicle and estradiol-stimulating hormone levels in tamoxifen users.", "- Exclusion criteria:", "The exclusion criteria are current depression, history of migraines or hepatitis, abnormal chemical profile (e.g., sodium, potassium, glucose) or positive detection of illegal substances in the urine."], "Results": ["Performance measures:", "Serum levels of Tryptophan", "Mean serum tryptophan (blood extraction) at the end of the nadir period.", "Duration: base, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours", "Results 1:", "Title of arm/group: Acute Depletion of Tryptophan at full strength", "Description of arm/group: [Unspecified]", "Total number of participants analysed: 24", "Average (standard deviation)", "Unit of measurement: nmol/ml 0.0034 (.0027)", "Results 2:", "Title of arm/group: Half-force Tryptophan Depletion - Control", "Description of arm/group: [Unspecified]", "Total number of participants analysed: 23", "Average (standard deviation)", "Unit of measurement: nmol/ml 0.02 (0.02)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/0", "Adverse Events 2:", "Total: 0/0"]}